Olink Proteomics announces the availability of three new biomarker panels to further explore the complexities of the human proteome

Uppsala, Sweden, November 29, 2016 – Olink Proteomics today announced the launch of three new precision proteomics panels, significantly expanding its library of high quality human protein biomarker assays, from 460 to over 700. This series of new panels is designed to enable scientists to extend their discovery capabilities for studying the plasma proteome by casting a broader net, thereby maximizing their chances of identifying clinically relevant protein signatures. The focus areas for these three new panels are Immune Response, Organ Damage and Metabolism.

These panels build on the successful targeted discovery approach that Olink Proteomics established with its disease-focused panels for Cardiovascular Disease, Immuno-Oncology, Inflammation, Neurology and Oncology. The inclusion of some less well-established markers for those specific disease areas has enabled scientists to make some important novel findings, and the emphasis with the three new panels is shifted still further towards exploring the complexity of the human proteome. Panel design is focused around important biological processes with wide-ranging clinical relevance, making this series a powerful complement to the existing portfolio of panels for studies across a wide range of scientific questions and clinical areas.

As with Olink’s previous offerings, each panel offers simultaneous analysis of 92 protein biomarkers using just 1 µL of biological sample, and all assays are subject to strict technical validation and QC control procedures. To see more details about the new exploratory series of panels and the biomarker assays included, please visit our website.

““Having established our panels as a powerful tool for targeted biomarker discovery, this expansion of our product range now offers customers a true proteomics-scale solution for exploration of the human plasma proteome. This approach enables a wide proteomics net to be cast, which combined with our disease/biological process-focused panel design provides academic, clinical and pharma-biotech industry researchers with the flexibility to tailor our product offering to meet their specific needs.There is a genuine desire to move healthcare towards a precision medicine approach as quickly as possible, but this will require innovative, reliable tools that can deliver the critical knowledge required. Olink intends to enable this journey, providing an expanding library of high quality biomarker assays backed by improved bioinformatic data support. The launch of these new panels represents an important step towards those goals, with much more to come in the near future”.

” says Andrea Ballagi, VP Sales & Marketing at Olink Proteomics.

Product and technology information
Each panel offers high-throughput multiplex immunoassays that measure 92 proteins simultaneously using only one microliter of serum, plasma, tumor cell lysate, or almost any other type of biological sample. Thousands of samples per week can be analyzed using these panels, which greatly accelerates the speed of protein biomarker discovery.

Olink’s assays are based on the proprietary Proximity Extension Assay (PEA) technology developed by Olink. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR. This dual recognition, DNA-coupled method provides exceptional readout specificity and enables the panels to achieve a combination of high multiplexing level and data quality that cannot be matched using standard immunoassay techniques. An animation overviewing how the technology works and what it is used for can be viewed on Olink’s YouTube channel.

For research use only. Not for use in diagnostic procedures.

About Olink Proteomics
Through our dedication to innovation, quality, rigor and transparency, Swedish company Olink Proteomics’ groundbreaking solutions help scientists make research decisions more quickly and confidently through robust, multiplex biomarker analysis. Our immunoassay panels enable rapid, high-throughput analysis with exceptional data quality and minimal consumption of precious biological samples. Only 1 µL of sample is needed to address 92 biomarkers simultaneously and each panel is sufficient for 96 samples, generating more than 9 000 data points from each run. Each panel is focused on a specific area of disease or biology, targeting 92 validated and/or exploratory biomarkers that have been carefully selected in collaboration with leading experts in the field. All assays are rigorously quality controlled and our validation data is made freely available. Customers can obtain the panels as ready-to-use kits to run the assays themselves, or can choose to let our in-house experts run their samples for them, using our Analysis Service in Uppsala or Boston.

Olink Proteomics is headquartered in Uppsala, Sweden, with a regional office and service laboratory for the U.S. organization in Watertown, MA.

For more information, please visit www.olink.com.

Proseek^® is a registered trademark of Olink Proteomics AB.

Olink^® is a registered trademark of Olink Bioscience AB.

Contact information
Andrea Ballagi, MD, PhD, MBA
VP Sales & Marketing
Phone: +46-18-444 3970
E-mail: info@olink.com